The affected functions may include T-cell responses, B-cell responses, innate immunity, or several of these together. This distinction matters because a model lacking one immune component does not reproduce the same biological setting as one with broader immunodeficiency. Matching the impaired function to the research question helps investigators interpret host defense, disease, transplantation, or treatment findings more precisely.
Targeted genetic mutations change immune capacity through an inherited model feature, whereas selective depletion removes particular immune cells as an experimental intervention. Other interventions may also limit immune responses without targeting the same component. These approaches create different biological contexts, so the choice determines which aspects of host defense or disease-related immunity can be examined.
Reduced immune rejection allows certain transplanted human cells or tissues to remain available for investigation in the mouse. Researchers can therefore examine disease-related behavior, host interactions, or responses to therapy in a controlled living system. The model does not recreate a fully normal immune environment, however, so findings must be interpreted in light of the missing or weakened defenses.
Compared with immunocompetent mice, immune-compromised mice provide a setting in which selected immune barriers are weakened or absent. This can make them useful for questions that require human cells or tissues, but it also changes normal host biology. Consequently, results about infection, disease, or treatment response may not translate directly to animals with intact immunity.
Model selection should begin with the biological question and the immune function that needs to be limited. Investigators can then consider whether the study concerns host defense, human cell or tissue transplantation, disease mechanisms, or therapy response. Choosing a model whose deficiency matches that purpose improves experimental relevance while making its limitations easier to recognize.
In preclinical medicine, these mice support studies of infections, cancer, transplantation, immune disorders, and drug responses. Their value comes from allowing researchers to analyze disease mechanisms and therapeutic effects under controlled conditions, including settings involving human cells or tissues. Each application still requires attention to how the model’s altered immunity shapes the observed outcome.
Treatment studies can provide information about drug responses and therapeutic efficacy, while disease studies can reveal mechanisms relevant to human conditions. When human cells or tissues are examined, the model may also help assess how those transplanted materials behave within a living host. These outcomes are preclinical evidence, not a complete substitute for normal immune biology.
Because immune compromise changes the biology being measured, study design must account for more than the intervention itself. A disease or drug result may be shaped by the weakened or absent immune response, especially when conclusions concern host defense or treatment efficacy. Recognizing this limitation helps researchers avoid treating model-specific findings as if they represented intact immunity.